Présentation de l'entreprise
Intelligent Bio Solutions Inc. operates as a specialized medical technology firm dedicated to the development and deployment of non-invasive testing and screening solutions across the Asia Pacific region, the United States, the United Kingdom, and international markets. The company focuses specifically on intelligent fingerprinting drug screening systems, a platform designed to facilitate rapid identification and analysis without the need for invasive procedures. This entity functions within the Healthcare sector, specifically targeting the Medical Devices industry, which implies a focus on tangible assets used in clinical settings to aid in diagnostics and patient safety. The company currently maintains a market capitalization of $5.30M and reports annual revenue of $3.58M, supported by an operational workforce of 53 employees. These valuation and revenue figures indicate that Intelligent Bio Solutions Inc. is a micro-cap enterprise with a relatively small scale, suggesting limited market penetration and a niche operational footprint within the broader healthcare device ecosystem.
Santé financière
The company generated revenue of $3.58M over the trailing twelve-month period, yet reported a net income of $-11,294,226 and an EBITDA of $-9,836,561, revealing a significant structural disconnect where operating expenses substantially exceed total revenue generation. The reported free cash flow stands at $-14,541,733, indicating that the company is currently consuming cash reserves rather than generating liquidity from its core operations. The gross margin stands at 46.2%, demonstrating that the cost of goods sold consumes less than half of the revenue, while the operating margin of -290.9% and profit margin of 0.0% highlight severe inefficiencies or high overhead costs that erade profitability at the operational and net levels. Regarding liquidity and leverage, the firm holds $740,371 in cash against $1.92M in debt, resulting in a debt-to-equity ratio of 17.67 which signifies a highly leveraged balance sheet where liabilities significantly outweigh equity. The current ratio is recorded at 2.38, suggesting that the company possesses sufficient current assets to cover its short-term liabilities more than twice over, though this liquidity may be constrained by the negative free cash flow. Return on Equity is calculated at -150.2% and Return on Assets at -51.2%, metrics that reveal management has yet to generate positive returns on shareholder capital or the asset base, reflecting a period of significant financial strain and operational losses.
Évaluation de la valorisation
The trailing twelve-month P/E ratio is N/A due to the net loss position, while the forward P/E is listed at 7.57, implying market expectations that earnings will turn positive or stabilize in the near future despite current deficits. The price-to-book ratio is 0.30, indicating that the stock trades at significantly less than its book value, which often suggests the market is pricing in substantial risks or a lack of near-term earnings potential. The price-to-sales ratio stands at 1.48 and the EV/EBITDA is -0.53, providing alternative valuation perspectives that highlight the company's negative earnings power and high revenue relative to its enterprise value. Over the past year, the stock price has fluctuated between a 52-week low of $2.53 and a 52-week high of $24.90, showing extreme volatility and a wide trading range typical of speculative small-cap biotech or device stocks. The beta value is 4.59, which quantifies the stock's extreme sensitivity to market movements, meaning the asset is expected to fluctuate with a magnitude roughly 4.59 times greater than the broader market index.
Growth & Income
Revenue growth accelerated to 47.6% year-over-year, while earnings growth is N/A due to the company's loss-making status, indicating that top-line expansion has not yet translated into bottom-line profitability. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company retains all of its earnings, if any, to reinvest into research, development, and operational scaling rather than distributing income to shareholders. The absence of a dividend payout confirms the firm's strategy of funding growth internally through retained earnings or external financing rather than providing income streams to investors. Overall, the growth and income profile is characterized by rapid top-line expansion coupled with significant financial losses and a lack of current income distribution, positioning the company as a high-risk, high-potential growth vehicle rather than a value or income investment.